Wednesday, June 15, 2016 10:16:06 AM
Neurodegenerative disease treatment company, Cantabio Pharmaceuticals Inc. (OTCQB: CTBO) has seen shares rise 6.40% in early morning trading on Tuesday, June 14, 2016. Over the past month, Cantabio Pharmaceuticals Inc. (OTCQB: CTBO) has seen average daily volume stand around 61,776 shares and the pharmaceutical company is on track to see share volume expand over its daily average, as nearly 40,000 shares or around $82,000 in dollar volume has already exchanged hands.
The Palo Alto, CA-based company has not seen any new updates hit the news waves, but Cantabio Pharmacetuicals Inc. (OTCQB: CTBO) was subject of a Seeking Alpha post that was published on June 13, 2016. In the article by Stone Fox Capital, the author acknowledges the risks and drawbacks to the company, but says “the small biotech has promising drug candidates in an area of extreme unmet needs and in need of workable solutions,” (Seeking Alpha). Alzheimer’s, dementia, and other neurodegenerative diseases continue to pose major health care issues, as limited treatment options are available.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM